Idelalisib plus bendamustine and rituximab (BR) is superior to BR alone in patients with relapsed/refractory chronic lymphocytic leukemia: Results of a phase 3 randomized double-blind placebo-controlled study

被引：0
|
作者：
Zelenetz, A. [1 ]
Robak, T. [2 ,3 ]
Coiffier, B. [4 ]
Delgado, J. [5 ]
Marlton, P. [6 ]
Adewoye, A. [7 ]
Kim, Y. [7 ]
Dreiling, L. [7 ]
Hillmen, P. [8 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Dept Med, Lymphoma Serv, 1275 York Ave, New York, NY 10021 USA
[2] Med Univ Lodz, Lodz, Poland
[3] Copernicus Mem Hosp, Lodz, Poland
[4] Hosp Civils Lyon, Pierre Benite, France
[5] Hosp Clin Barcelona, Dept Hematol, Barcelona, Spain
[6] Princess Alexandra Hosp, Dept Clin Haematol, Brisbane, Qld 4102, Australia
[7] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA
[8] St James Univ Hosp, Dept Haematol Oncol, Leeds LS9 7TF, W Yorkshire, England
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2016年 / 173卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
10
引用
收藏
页码：10 / 10
页数：1
相关论文
共 50 条
  • [31] Final 5-year updated results from a phase 3 study (HELIOS) of ibrutinib plus bendamustine and rituximab (BR) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)
    Fraser, Graeme
    Chanan-Khan, Asher
    Demirkan, Faith
    Silva, Rodrigo Santucci
    Grosicki, Sebastian
    Janssens, Ann
    Mayer, Jiri
    Bartlett, Nancy
    Dilhuydy, Marie Sarah
    Loscertales, Javier
    Avigdor, Abraham
    Rule, Simon
    Samoilova, Olga
    Pavlosky, Miguel
    Hallek, Michael
    Salman, Mariya
    Tamegnon, Monelle
    Sun, Steven
    Connor, Anne
    Nottage, Kerri
    Balasubramanian, Sriram
    Howes, Angela
    Cramer, Paula
    LEUKEMIA & LYMPHOMA, 2020, 61 : 106 - 108
  • [32] A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib and rituximab for previously treated patients with chronic lymphocytic leukaemia (CLL) (NCRN375)
    Hillmen, P.
    Furman, R.
    Sharmann, J.
    Coutre, S.
    Cheson, B.
    Pagel, J.
    Barrientos, J. M.
    Zelenetz, A.
    Kipps, T.
    Pettitt, A.
    Wallis, J.
    Duncombe, A.
    Dearden, C.
    Follows, G.
    MacDonald, D.
    Moosa, A.
    Panoskaltsis, N.
    De Lord, C.
    McCarthy, H.
    O'Brien, S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2014, 165 : 3 - 3
  • [33] RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF PANOBINOSTAT OR PLACEBO PLUS BORTEZOMIB AND DEXAMETHASONE IN RELAPSED OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA (PANORAMA 1)
    San-Miguel, J.
    Hungria, V. T.
    Yoon, S. S.
    Beksac, M.
    Dimopoulos, M. A.
    Elghandour, A.
    Jedrzejczak, W. W.
    Guenther, A.
    Nakorn, T. Na
    Siritanaratkul, N.
    Schlossman, R. L.
    Hou, J.
    Moreau, P.
    Lonial, S.
    Lee, J. H.
    Einsele, H.
    Salwender, H.
    Sopala, M.
    Bengoudifa, B. R.
    Corrado, C.
    Binlich, F.
    Richardson, P.
    HAEMATOLOGICA, 2014, 99 : 219 - 220
  • [34] A Phase III, Randomized, Double-Blind, Study of Tazemetostat or Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory Follicular Lymphoma
    Salles, Gilles
    Shah, Harsh
    Leonard, John P.
    Szanto, Attila
    Chen, Jade
    Bannerji, Rajat
    Morschhauser, Franck
    Nastoupil, Loretta J.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S454 - S455
  • [35] Acalabrutinib versus rituximab plus idelalisib or bendamustine in relapsed/refractory chronic lymphocytic leukemia: ASCEND results at 4 years of follow-up.
    Jurczak, Wojciech
    Pluta, Andrzej
    Wach, Malgorzata
    Lysak, Daniel
    Simkovic, Martin
    Kriachok, Iryna
    Illes, Arpad
    De la Serna, Javier
    Dolan, Sean
    Campbell, Philip
    Musuraca, Gerardo
    Jacob, Abraham
    Avery, Eric Joseph
    Lee, Jae Hoon
    Usenko, Ganna
    Wang, Min Hui
    Yu, Ting
    Ghia, Paolo
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [36] Acalabrutinib vs rituximab plus idelalisib or bendamustine in relapsed/refractory chronic lymphocytic leukemia: ASCEND results at ∼4 years of follow-up
    Welslau, M.
    Jurczak, W.
    Pluta, A.
    Wach, M.
    Lysak, D.
    Simkovic, M.
    Kriachok, I
    Illes, A.
    De la Serna, J.
    Dolan, S.
    Campbell, P.
    Musuraca, G.
    Jacob, A.
    Avery, E. J.
    Hoon, Lee J.
    Usenko, G.
    Wang, M. H.
    Yu, T.
    Ghia, P.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 118 - 119
  • [37] Acalabrutinib vs Rituximab Plus Idelalisib or Bendamustine in Relapsed/Refractory Chronic Lymphocytic Leukemia: ASCEND Results at ∼4 Years of Follow-up
    Welslau, Manfred
    Jurczak, Wojciech
    Pluta, Andrzej
    Wach, Malgorzata
    Lysak, Daniel
    Simkovic, Martin
    Kryachok, Irina
    Illes, Arpad
    De la Serna, Javier
    Dolan, Sean
    Campbell, Philip
    Musuraca, Gerardo
    Jacob, Abraham
    Avery, Eric
    Lee, Jae Hoon
    Usenko, Ganna
    Wang, Min Hui
    Yu, Ting
    Ghia, Paolo
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 170 - 170
  • [38] Results of a Phase 2 Study of MEDI-551 and Bendamustine Vs Rituximab and Bendamustine in Relapsed or Refractory Chronic Lymphocytic Leukemia
    Gladstone, Douglas
    Andre, Marc
    Jan Zaucha
    Assouline, Sarit
    Bellam, Naresh
    Cascavilla, Nicole
    Jourdan, Eric
    Panwalkar, Amit
    Patti, Caterina
    Schulte, Clemens
    Zaja, Francesco
    Goswami, Trishna
    Elgeioushi, Nairouz
    Streicher, Katie
    Bao, Haifeng
    Spaner, David
    BLOOD, 2014, 124 (21)
  • [39] SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib versus Bendamustine plus Rituximab (BR) in Patients with Treatment-Naive (TN) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
    Tam, Constantine S.
    Giannopoulos, Krzysztof
    Jurczak, Wojciech
    Simkovic, Martin
    Shadman, Mazyar
    Osterborg, Anders
    Laurenti, Luca
    Walker, Patricia
    Opat, Stephen
    Chan, Henry
    Ciepluch, Hanna
    Greil, Richard
    Tani, Monica
    Trneny, Marek
    Brander, Danielle M.
    Flinn, Ian W.
    Grosicki, Sebastian
    Verner, Emma
    Brown, Jennifer R.
    Kahl, Brad S.
    Ghia, Paolo
    Tian, Tian
    Marimpietri, Carol
    Paik, Jason C.
    Cohen, Aileen
    Huang, Jane
    Robak, Tadeusz
    Hillmen, Peter
    BLOOD, 2021, 138
  • [40] SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib Versus Bendamustine plus Rituximab (BR) in Patients With Treatment-Naive (TN) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
    Kahl, Brad S.
    Giannopoulos, Krzysztof
    Jurczak, Wojciech
    Simkovic, Martin
    Shadman, Mazyar
    Osterborg, Anders
    Laurenti, Luca
    Walker, Patricia
    Opat, Stephen
    Chan, Henry
    Ciepluch, Hanna
    Greil, Richard
    Tani, Monica
    Trneny, Marek
    Brander, Danielle M.
    Flinn, Ian W.
    Grosicki, Sebastian
    Verner, Emma
    Brown, Jennifer R.
    Ghia, Paolo
    Li, Jianyong
    Tian, Tian
    Zhou, Lei
    Marimpietri, Carol
    Paik, Jason C.
    Cohen, Aileen
    Robak, Tadeusz
    Hillmen, Peter
    Tam, Constantine S.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S269 - S270
12345